The importance of the general practitioner as an information source for patients with hereditary haemochromatosis by Teixeira, Emerência et al.
Accepted Manuscript
Title: The Importance of the General Practitioner as an
Information Source for Patients with Hereditary
Haemochromatosis
Author: Emereˆncia Teixeira Ju´lio Borlido-Santos Pierre
Brissot Barbara Butzeck Franc¸oise Courtois Robert W. Evans
Janet Fernau Joa˜o Arriscado Nunes Margaret Mullett Milena
Paneque Brigitte Pineau Grac¸a Porto Robert Sorrill Mayka
Sanchez Dorine W. Swinkels Ketil Toska Judit
Varkonyi<ce:collaboration
id="colb0005"></ce:collaboration>
PII: S0738-3991(14)00178-5
DOI: http://dx.doi.org/doi:10.1016/j.pec.2014.04.017
Reference: PEC 4779
To appear in: Patient Education and Counseling
Received date: 27-11-2013
Revised date: 12-4-2014
Accepted date: 28-4-2014
Please cite this article as: Teixeira E, Borlido-Santos J, Brissot P, Butzeck B, Courtois,
F, Evans RW, Fernau J, Nunes JA, Mullett M, Paneque M, Pineau B, Porto G, Sorrill R,
Sanchez M, Swinkels DW, Toska K, Varkonyi J, the EFAPH, the-European Federation
of Associations of Patients with Haemochromatosis, The Importance of the General
Practitioner as an Information Source for Patients with Hereditary Haemochromatosis,
Patient Education and Counseling (2014), http://dx.doi.org/10.1016/j.pec.2014.04.017
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 25
Ac
ce
pte
d M
an
us
cri
pt
  1
The Importance of the General Practitioner as an Information Source 
for Patients with Hereditary Haemochromatosis 
Emerência Teixeira1,2, Júlio Borlido-Santos1, Pierre Brissot3, Barbara Butzeck4,21, 
Françoise Courtois,10,21, Robert W. Evans5,6, Janet Fernau6, João Arriscado Nunes7, 
Margaret Mullett8, Milena Paneque1,9, Brigitte Pineau10, Graça Porto1,9,11,12, Robert 
Sorrill13, Mayka Sanchez14,15, Dorine W. Swinkels16,17, Ketil Toska18, Judit Varkonyi19, 20 
and the EFAPH, the-European Federation of Associations of Patients with 
Haemochromatosis21 
1. IBMC – Institute for Molecular and Cell Biology, University of Porto, Rua do Campo 
Alegre, 823, 4150‐180 Porto, Portugal; 
2. FCUP – Faculty of Science, University of Porto, Rua do Campo Alegre, 4150‐180 
Porto, Portugal. 
3. National Reference Centre for Rare Iron Overload Disorders of Genetic Origin and 
Inserm U-991. Pontchaillou University Hospital, Rennes, France. 
4.Haemochromatose-Vereinigung Deutschland e.V.(HVD), Koln, Germany. 
5. Doctor-on-a-Chip Laboratory, Department of Electronic and Computer Engineering, 
School of Engineering and Design, Brunel University, Uxbridge, Middlesex,  UB8 3PH, 
UK. 
6. The Haemochromatosis Society, Hollybush House, Hadley Farm Road, Barnet, 
Hertfordshire, EN5 5PR, UK. 
7. CES – Centre for Social Studies, University of Coimbra, Coimbra, Portugal. 
8. Irish Haemochromatosis Association, Dublin, Ireland. 
9. CGPP – Centre for Predictive and Preventive Medicine, Porto, Portugal. 
10. FFAMH - Fédération Française des Associations de Malades de l'Hemochromatose, 
France. 
Page 2 of 25
Ac
ce
pte
d M
an
us
cri
pt
 2
11. CHP-HSA, Porto Hospital Center - Santo António Hospital, Porto, Portugal. 
12. Associação Portuguesa de Hemocromatose, Porto, Portugal. 
13. Associazione per lo Studio di Emocromatosi e delle Malattie da Sovraccarico di 
Ferro, Monza, Italy. 
14. IMPPC – Institute of Predictive and Personalized Medicine of Cancer, Badalona, 
Barcelona, Spain. 
15. IJC- Josep Carreras Leukemia Research Institute, Barcelona, Spain.  
16. Department of Laboratory Medicine, Laboratory of Genetic, Endocrine and Metabolic 
diseases (LGEM 830) Radboud University Medical Centre, Nijmegen, the Netherlands. 
17. Hemochromatose Vereniging Nederland, AG Leidschendam, the Netherlands. 
18. Norwegian Haemochromatosis Association, Bergen, Norway  
19. 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary. 
20.  Hemokromatozisos Betegek Eyesülete, Budapest, Hungary. 
21. EFAPH-European Federation of Associations of Patients with Haemochromatosis, 
Croissy-sur-Seine, France. 
 
Corresponding author at: 
Graça Porto, MD, PhD  
Address:  
IBMC – Institute for Molecular and Cell Biology University of Porto 
Basic & Clinical Research on Iron Biology 
Rua do Campo Alegre, 823 
4150-180 Porto 
Portugal 
  
Telephone number: +351226074900 
Fax number: +351226099157 
E-mail Address: GPorto@ibmc.up.pt 
 
 
 
Page 3 of 25
Ac
ce
pte
d M
an
us
cri
pt
  3
 
Abstract 
Objective: To explore Hereditary Haemochromatosis (HH) patients’ perspectives on 
genetic information, namely the types of sources used, preferred or trusted.  
Methods: A survey online was conducted by the European Federation of Associations 
of Patients with Haemochromatosis (EFAPH) and applied to members of 9 national 
associations.  
Results: From a total of 1019 validated questionnaires, 895 respondents had 
performed a genetic testing for HH. From these, 627 self-declared that they were 
sufficiently informed about the implications of the genetic test to their health. The 
majority (66%) obtained the information from a specialist doctor, but would like to obtain 
it from the family doctor. However, the specialist was still the one they trusted more 
(69%). Regarding the 298 respondents who did not feel sufficiently informed, the 
majority (78%) also would like to have information from the family doctor although they 
also trusted the specialist more (75%). A different perspective was reported when patients 
were asked about the implications of the genetic testing to their family members, where 
the majority of respondents referred obtaining information from a specialist (69%). 
Conclusion: This study elucidates the patients´ needs for information and identifies the 
General Practitioner (GP) as the preferred source to obtain information about HH. 
Practice Implications: These results may have important implications in future strategies 
for HH awareness, giving a special emphasis on GPs as the main players.  
 
Keywords 
Hereditary Haemochromatosis; Patient Communication; Sources of Information; General 
Practitioner.  
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1. Introduction 
Patient-centered medicine (i.e., care in which the doctor responds to the 
patients’ needs, including their thoughts or feelings), is a recent a buzz-word [1]. 
This concept became most popular after its comprehensive description by Brown 
and co-workers in 1995 [2] when identified several interconnecting components 
which included the enhancement of doctor-patient relationships. It is also 
increasingly evident that patients want to be fully informed and be part of the treatment 
decision making. They have a better idea of their requirements, and are able to verbalize 
their needs and preferences when they are invited to do so [3]. There is evidence that 
informed patients are better aware of matters relating to their care and therefore they 
should also be better placed to take an active part in their own care [4] and improve the 
quality and responsiveness of health care services. Nevertheless, to our knowledge, no 
sufficient attention has been paid to the patients’ perspectives on the sources they use to 
obtain information on genetic disorders. 
HH is one of the most common adult-onset genetic disorders in European-derived 
populations [5]. It is a chronic disorder which occurs when the normal regulation of iron 
absorption is disrupted resulting in the accumulation of excessive iron in the liver, 
pancreas, heart and joints leading to organ damage, and impaired function [6]. In spite of 
being a potentially lethal disease, early diagnosis of HH and treatment by venesections 
can restore normal life expectancy, reduce symptoms, and help to prevent organ damage 
[7]. In contrast, failure to detect HH increases the likelihood that irreversible adverse 
health effects will occur and increases the future financial burden associated with health 
care for persons with HH [8]. These findings have led to recommendations for increased 
case detection and universal screening using phenotypic testing (eg, transferrin saturation) 
to permit early treatment before the onset of clinical disease [9]. Moreover, taking into 
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consideration the healthy status of early diagnosed HH carriers, the potential use of 
their blood for transfusion is nowadays an issue of major interest [10]. 
Early detection and treatment of HH depends on increased awareness and proper 
information among health professionals and patients themselves, who play an important 
role in the motivation and spread of information among their relatives. In spite of these 
recommendations, much of the literature suggests that HH is still largely underdiagnosed 
and therefore undertreated [11-13], a position that was also recognized by  the European 
Commission in response to a parliamentary question promoted by the European 
Federation of Patients with Haemochromatosis (EFAPH) (E-012656/2011). 
In general, there is a paucity of information about the patients’ perceptions about 
HH and, to our knowledge, no studies have ever been performed regarding the sources of 
information they find useful [8, 14]. This is particularly relevant in Europe where, in spite 
of a low clinical penetrance, the genetic condition is highly prevalent [5]. That question 
was addressed in this study in which members of nine patients’ associations were invited 
to participate in an international survey online. The survey was designed to understand 
which sources are used by patients or subjects at risk to find information about HH, where 
do they prefer to get it from, where they would like to find it, and which information 
sources they trust more.  
Our expectation is that the results of this study will be useful for the 
implementation of new strategies on HH awareness and consequently may contribute to 
increase early diagnosis of the disease. 
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2. Methods 
2.1. The questionnaire  
Members from nine National Associations of Patients with Haemochromatosis, all 
EFAPH members, (France, Germany, Hungary, Italy, Ireland, Netherlands, Norway, 
Portugal and United Kingdom) were enrolled in the present study regarding genetic 
testing and the sources of information used to find information about HH. They were 
invited to answer to a survey posted online by EFAPH, using the SurveyMonkey platform. 
The survey online was preferred as a suitable and economical method for data collection 
because our target population was large and our measurements focused on patients’ own 
perceptions [15]. A copy of the survey is available from the authors upon request. 
Because this is the first survey of its kind, there was no available a priori 
information to guide our strategy to identify the sources of information usually used by 
the associations’ members. Therefore various steps were taken to ensure the validity and 
reliability of the study. Initially, the study design was evaluated by a committee 
composed of the coordinators of the Biosense project, an experimental platform of 
engagement and collaboration between Portuguese academic and scientific research 
institutions and the society, inspired by the European concept of science shop [16]. 
Next the questionnaire format and questions were discussed among members of the 
Scientific Committee of EFAPH and sent to 3 patients’ representatives, namely from 
Germany, Ireland and Norway, for validation through a pre-testing exercise where 
they responded to the questions and pointed out possible interpretation difficulties 
or shortcomings. After this validation, the Scientific Committee approved the 
English version of the questionnaire. This final version was sent to 9 local 
coordinators nominated for each participating Association. Whenever necessary, 
i.e., for non English-speaking populations (Dutch, English, French, German, 
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Hungarian, Italian and Portuguese) the local coordinators had to translate the 
questionnaire into their own native language, without editing or modifying its 
content. Next the coordinators were responsible for pre-testing the survey online 
format (including detailed answering instructions) before making it public. They 
were further responsible for contacting all registered members of the respective 
Associations (without any exclusion), inviting and motivating them to participate in 
the study. For this purpose, each local coordinator was sent a suggested model letter that 
could be used to approach the members stating their voluntary participation and 
anonymous nature of the study. This process started in November 2011 and finished in 
July 2012. During this period two reminder e-mails were sent to local coordinators. 
 The cover page of the questionnaire explained the objective of the study and 
contained elements of informed consent (including an opt-out option), so that 
participants only answered the survey after acceptance of the conditions. 
 
2.2. Data collection, sampling and contents 
Data were mostly obtained from the electronic version of the survey, but in two 
cases (Germany and Portugal) the questionnaires were sent by post to the coordinator 
who then transferred the data to the SurveyMonkey platform. The local coordinator was 
also responsible for the translation of the answers. Demographic data were collected in 
order to characterize the sample, including gender, age, nationality, years of education 
and occupation. The respondents’ answers about age were displayed as six categories 
(<25; 25-35; 35-45; 45-55; 55-65; 65-75 and >75 years old) and answers about 
occupation into fourteen categories (according to the International Standard Classification 
of Occupations [17]).  
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Participants were first asked if they had ever undergone a genetic test. Only 
respondents who answered affirmatively were allowed to continue with the 
questionnaire and be validated as participants. This strategy was used as a means to 
optimize the sample in terms of representing a population of patients or patients at 
risk. Participants were then asked if they felt whether or not they were sufficiently 
informed about the genetic testing and its implications to their health. According to their 
response to this question, respondents were segregated in two groups for further analyses, 
(i.e., those who answered “yes” and those who answered “no”). They were further asked 
where they would like to find (or find more) information about HH and which 
information sources they trusted more. Sources of information displayed included: Family 
Doctor, Specialist, Scientist, Nurse, Internet - Official Website (ex: Hospital and 
University), Internet – Other Website (ex: Wikipedia, Blogs, Facebook, Twitter), Books, 
Papers and Magazines, Associations of Patients, Family and Friends or Other (free 
answer). 
 
2.3. Analysis 
We computed descriptive statistics (means, standard deviations, and proportions) 
of the variables and examined the distributions of the responses. Differences in 
distributions were analyzed by the Chi-Square test with IBM SPSS Statistics 19. 
 
2.4. Ethics 
The basic principles of research ethics were followed at all stages of the study. All 
the data were handled confidentially according to the principles stated in the Helsinki 
Declaration [18].  
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3. Results  
Three thousand nine hundred and seventy three members were invited to 
participate and 1032 (26%) answered the questionnaire. From the total population of 
1032 respondents, 13 were excluded because they had supplied only partial replies to 
demographic questions and did not proceed with the questionnaire. In addition, 124 
respondents had not had a genetic test and were therefore excluded from the 
analyses. The remaining 895 respondents who declared to have performed a genetic 
test were considered for further analyses. A schematic representation of sample 
collection and processing is given in Figure 1. The average age of respondents was 55. 7 
+ 11.7 years (mean + standard deviation), 58% were males and 42% were female. Thirty 
eight percent of the participants were graduates and 30% of the participants were included 
in major group 2, Professionals, and 21% of total number of participants were retired. The 
distribution of participants by nationality is recorded in Table 1. 
When asked if they “feel sufficiently informed about your genetic testing and its 
implications to your health?” 70% answered “yes” and 30% answered “no”. The 
respondents that felt sufficiently informed were aged between 55-65 years and the 
respondents that did not feel sufficiently informed were 45-55 years old. 
Regarding the respondents that answered “yes” to the above question, when asked  
“where did you get information?”, the majority reported that their main source of 
information was the specialist (66%), 39% referred to the family doctor and 38% to 
Patients Associations (Table 2 and Fig. 2). When data were analyzed by National 
Associations we observed that they all obtained information mainly from the specialist, 
except the participants from Irish Haemochromatosis Society, who obtained information 
mainly from their family doctors. 
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When asked “where would you like to find information?”, a higher percentage 
expressed a preference for obtaining information from the family doctor (66%), while a 
lower percentage preferred the specialist (59%) or the patient association (44%) (Table 2 
and Fig. 2). Nevertheless, when asked “Of those sources of information, in which do you 
trust more?” the majority mentioned the specialist (69%) followed by the Patient 
Association (41%) or the family doctor (31%) (Table 2 and Fig. 2). 
Regarding the respondents who answered “no” to the question “Do you feel 
sufficiently informed about your genetic testing and its implications to your health?”, the 
majority preferred to obtain information from their family doctor (78%), closely followed 
by a specialist (77%), with the third preference being official websites on the internet 
(53%) (Table 2 and Fig. 3). Such as in the case of informed participants, these also trusted 
more in the specialist (75%), rather than the family doctor (35%) or Patient Association 
(24%) (Table 2 and Fig. 3). 
We also asked the participants if they “feel sufficiently informed about the 
implications of your genetic testing to other family members”: 78% answered “yes” and 
22% answered “no”. 
Of the respondents who answered “yes” to the question above, when asked “where 
did you get information?”,  the majority reported that their main source of information 
was the specialist (72%). The specialist was also the preferred source (69%) and whom 
they trusted more (68%) (Table 3). 
Of the  respondents who answered “no” to the question “Do you feel sufficiently 
informed about the implications of your genetic testing to other family members” 77% 
stated that they would like to obtain the information from the specialist and 72% had 
more trust in the specialist (Table 3). 
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4. Discussion and conclusion 
4.1. Discussion 
This is the first European survey designed to explore patients’ perspectives 
on genetic information. The main motivation to perform this study was the general 
concern about HH underdiagnosis and undertreatment, suggesting that both 
clinicians and laypeople have little awareness of the disease. Therefore HH 
awareness needs to be improved. In order to optimize resources, we did not 
approach all possible intervenients (such as health professionals, patients in general, 
etc) but decided to target a potentially “informed” HH population. It is well known 
that informed patients are better aware of matters relating to their care [3]. For that 
purpose we chose the members of Patients’ Associations who are “a priori” more 
likely to be informed. We asked them where they obtained the information, namely 
the types of sources used, preferred or trusted.  
Results of the questionnaire revealed that 70% of respondents reported that they 
felt sufficiently informed about genetic testing and its implications to their health. 
However, a lower percentage (55%) that they were sufficiently informed about the 
implications to their family members.  
The results reveal that respondents would like to receive more information about 
HH from the family doctor, despite having more trust in the specialist. This highlights the 
importance of targeting GPs as an important requested source of information. This is not 
surprising, since it had been already reported that about half of HH diagnoses are 
performed by a gastroenterologist, a hematologist and some other specialist physician, as 
opposed to being diagnosed by a primary care provider [14]. A recent study in Australia 
[7] showed that of 80% of GPs who reported that they had patients with HH, only 41% 
managed the condition primarily.  
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The participants from Irish Haemochromatosis Society were the only ones who 
answered that they obtained information about genetic testing mostly from the family 
doctor. This is interesting and probably reflects a commitment of GPs in Ireland to 
promote the diagnosis, treatment and management of patients with HH in the Primary 
Care Setting, in collaboration with the Irish Haemochromatosis Association [19]. This 
could also reflect the very high frequency of HH encountered by GPs in Ireland  
compared to those in other countries where the disease is not so common. As the GPs in 
Ireland have more cases of patients with HH they are more informed about the disease 
and thus their patients receive better treatment.  
The results showed that participants also used the internet as a source of 
information. We are aware that web-based information is a valuable resource for patients 
with many conditions although its reliability and quality have been questioned [20]. This 
is reflected in the results by the fact that a higher number of respondents selected official 
internet official websites rather than other websites. It is important to note that healthcare 
professionals have an important role in evaluating websites and directing patients and 
care givers to sites which provide accurate and up-to- date information [21]. 
In this study the respondents also recognized the specialists’ relevance in 
transmitting the information about genetic testing implications to other family members. 
In a recent study, Leandro and co-workers reported a general lack of knowledge about the 
selection of patient cases that should be sent for genetic counseling or for molecular 
testing of HFE-HH by physicians[22]. The lack of a primordial family-based screening 
may indirectly compromise the efficiency of disease prevention in terms of early 
diagnosis and treatment. A partnership between genetic counselors, medical geneticists, 
and primary care providers is also essential in order to develop effective policies, 
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educational tools, and practice guidelines, including the appropriate uses of genetic 
testing [23]. 
 
4.2. Limitations 
The fact that a high proportion of participants felt sufficiently informed can be 
explained by them being members of Patient Associations and thus being more motivated 
to find information about the disease. It could be suggested that this is a limitation of 
the study as it does not necessarily reflect the degree of awareness of HH population 
in general, eventually compromising the results’ generalization. However, we felt 
that by targeting an already informed population we could identify more effectively 
the focus of future actions to increase awareness about HH.  
The response rate was not as high as desired and this might limit the 
generalization of the results. Nevertheless, the Patient Associations’ members 
proved to be a good target population in terms of motivation, participation and 
geographic diversity. In addition, this study was able to identify some opportunities for 
stimulating and improving cooperation between associations and to create a feeling 
amongst the participants of the study that they are making an active contribution to 
the activities of their own associations.  
 
4.3. Conclusion 
In conclusion, the present study clearly identified the General Practitioner as being 
the preferred source for delivering specific information to HH patients about the disease 
and its implications to their health.  
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4.4. Practice Implications 
According to Acton [24] many physicians have an inadequate knowledge about 
HH diagnosis and the results reinforce the importance of GPs as a source of information 
about HH. Consequently these results may have important applications in future strategies 
for increasing awareness of the disease.  
We confirm that all patient/personal identifiers have been removed or disguised so 
the patient/person(s) described are not identifiable and cannot be identified through the 
details of this report. 
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Figure Legends 
 
Figure 1 
Outline of the sequence for subjects’ recruitment, data collection, validation and 
analysis. From a total of 3973 members from 9 European HH patients’ associations 
invited to participate, 1032 answered the questionnaire, and 1019 surveys were 
validated. Of these, 895 members stated that they had performed a genetic test and 
their responses were therefore considered for further analyses. 
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   Table 1 
   Demographic characteristics of the patients who have done a genetic test for HH (n=895) 
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Characteristics N Percentage 
378 42, 0 
Gender  
   Male  
   Female 517 58,0 
Age (years)  
   <25 3 0,3 
   25-35 41 4,6 
   35-45 142 15,9 
   45-55 243 27,2 
   55-65 274 30,6 
   65-75 166 18,5 
   >75 26 2,9 
Nationality   
   Dutch 33 3,7 
   French 26 2,9 
   Irish 194 21,7 
   German 165 18,4 
   Italian 155 17,3 
   Norwegian 67 7,5 
   Portuguese 29 3,2 
   United Kingdom 206 23,0 
   Other Country 20 2,2 
Yr education (n=760)  
   Level 0 – 0 years 46 6,1 
   Level 1 – 1 to 4 years  8 1,1 
   Level 2 – 5 to 8 years  29 3,8 
   Level 3 – 9 to 13 years 201 26,4 
   Level 4 – Graduate Degree 314 45,3 
   Level 5 – Postgraduate Education 52 6,8 
   Level 6 – Other 80 10,5 
Occupation (International Standard Classification of occupations)  
   Major Group 0 - Armed forces occupation 5 0,6  
   Major Group 1 - Managers 88 10,2 
   Major Group 2 - Professionals 264 30,6 
   Major Group 3 – Technicians and Associate Professionals 66 7,6  
   Major Group 4 - Clerical support workers 31 3,6  
   Major Group 5 - Service and sales workers 52 6,0 
   Major Group 6 - Skilled agricultural, forestry and fishery workers 2 0,2 
   Major Group 7 – Craft and related trades 30 3,5 
   Major Group 8 - Plant and machine operators, and assemblers 7 0,8 
   Major Group 9 - Elementary occupations 43 5,0 
   Other 77 8,9 
   None 3 0,3 
   Unemployed 7 0,8 
   Retired 188 21,8 
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Table 2 
Information sources about genetic testing and its implications to health, selected by 
respondents divided according to whether they do or do not consider themselves sufficiently 
informed. 
 
 
 
1 Information sources used by respondents to get information about genetic testing and its implications to their health. 
2 Information sources where respondents would like to find information about genetic testing and its implications to their 
health. 
3 Information sources which respondents trust more to find information about genetic testing and its implications to their 
health. 
 
Sufficiently Informed Not Sufficiently Informed  
 GET1 
(n=609) 
LIKE2 
(n=589) 
TRUST3 
(n=579) 
LIKE2 
(n=264) 
TRUST3 
(n=248) 
Family Doctor 236 38,8% 390 66,2% 181 31,3% 206 78,0% 87 35,1%Medical 
Sources Specialist 404 66,3% 349 59,3% 399 68,9% 202 76,5% 185 74,6%
Internet – Official 
Websites 
178 29,2% 252 42,8% 94 16,2% 141 53,4% 59 23,8%
Internet – Other 
Websites 
103 17,0% 98 16,6% 12 2,1% 38 14,4% 11 4,4% 
Association of Patients 231 37,9% 260 44,1% 237 40,9% 106 40,2% 59 23,8%
Non Medical 
Sources 
Scientist/Researcher 61 10,0% 83 14,1% 91 15,7% 48 18,2% 43 17,3%
Nurse 54 8,9% 79 13,4% 34 5,9% 50 18,9% 13 5,2% 
Books, Papers and 
Magazines 
75 12,3% 158 26,8% 17 2,9% 45 17,0% 7 2,8% 
Family or Friends 74 12,2% 21 3,6% 6 1,0% 15 5,7% 2 0,8% 
 
Other Source 45 7,4% 22 3,7% 10 1,7% 4 1,5% 0 0 
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Table 3 
Information sources about genetic testing and its implications to other family members, 
selected by respondents divided according to whether they do or do not consider themselves 
sufficiently informed. 
 
 
 
1 Information sources used by respondents to get information about genetic testing and its implications to other family 
members. 
2 Information sources where respondents would like to find information about genetic testing and its implications to 
other family members. 
3 Information sources which respondents trust more to find information about genetic testing and its implications to 
other family members. 
 
Sufficiently Informed Not Sufficiently Informed  
 GET1 
(n=648) 
LIKE2 
(n=624) 
TRUST3 
(n=600) 
LIKE2 
(n=184) 
TRUST3 
(n=177) 
Family Doctor 236 36,4% 416 66,7% 203 33,8% 137 74,5% 71 40,1%Medical 
Sources Specialist 466 71,9% 429 68,8% 410 68,3% 141 76,6% 127 71,8%
Internet – Official 
Websites 
187 28,9% 243 38,9% 108 18,0% 84 45,7% 32 18,1%
Internet – Other 
Websites 
65 4,2% 97 15,5% 10 1,7% 18 9,8% 7 4,0% 
Association of 
Patients 
273 17,7% 295 47,3% 240 40,0% 83 45,1% 45 25,4%
Non 
Medical 
Sources 
Scientist/Researcher 84 13,0% 104 16,7% 84 14,0% 43 23,4% 37 20,9%
Nurse 64 9,9% 86 13,8% 27 4,5% 36 19,6% 8 4,5% 
Books, Papers and 
Magazines 
67 10,3% 129 20,7% 17 2,8% 25 13,6% 2 1,1% 
Family or Friends 57 3,7% 26 4,2% 6 1,0% 11 6,0% 3 1,7% 
 
Other Source 47 3,0% 16 2,6% 13 2,2% 4 2,2% 5 2,8% 
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GET = Information sources used by respondents to get information about genetic testing and its implications to their health. 
LIKE = Information sources where respondents would like to find information about genetic testing and its implications to their 
health. 
TRUST = Information sources which respondents trust more to find information about genetic testing and its implications to their 
health. 
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LIKE = Information sources where respondents would like to find information about genetic testing and its implications 
to their health. 
TRUST = Information sources which respondents trust more to find information about genetic testing and its 
implications to their health. 
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